KAS
VRTX icon

Kestra Advisory Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Kestra Advisory Services’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.23M Sell
13,950
-481
-3% -$224K 0.02% 680
2025
Q4 		$6.54M Buy
14,431
+40
+0.3% +$17.2K 0.03% 586
2025
Q3 		$5.64M Buy
14,391
+33
+0.2% +$13.8K 0.03% 625
2025
Q2 		$6.39M Buy
14,358
+1,148
+9% +$529K 0.03% 531
2025
Q1 		$6.4M Sell
13,210
-3,048
-19% -$1.42M 0.03% 487
2024
Q4 		$6.55M Sell
16,258
-513
-3% -$238K 0.04% 480
2024
Q3 		$7.8M Sell
16,771
-2,973
-15% -$1.43M 0.04% 444
2024
Q2 		$9.25M Sell
19,744
-697
-3% -$303K 0.05% 386
2024
Q1 		$8.54M Buy
20,441
+2,425
+13% +$1.03M 0.06% 351
2023
Q4 		$7.33M Buy
18,016
+2,245
+14% +$829K 0.06% 338
2023
Q3 		$5.48M Buy
15,771
+464
+3% +$162K 0.05% 363
2023
Q2 		$5.39M Buy
15,307
+3,110
+25% +$1.05M 0.05% 350
2023
Q1 		$3.84M Sell
12,197
-9,768
-44% -$2.93M 0.04% 429
2022
Q4 		$6.34M Buy
21,965
+2,761
+14% +$841K 0.06% 355
2022
Q3 		$5.56M Sell
19,204
-2,822
-13% -$812K 0.06% 346
2022
Q2 		$6.21M Sell
22,026
-2,371
-10% -$635K 0.06% 311
2022
Q1 		$6.37M Buy
24,397
+5,720
+31% +$1.36M 0.07% 312
2021
Q4 		$4.1M Sell
18,677
-1,802
-9% -$350K 0.04% 425
2021
Q3 		$3.71M Sell
20,479
-2,320
-10% -$453K 0.04% 488
2021
Q2 		$4.6M Sell
22,799
-948
-4% -$198K 0.05% 379
2021
Q1 		$5.1M Buy
23,747
+18,503
+353% +$4.06M 0.06% 332
2020
Q4 		$1.22M Buy
5,244
+5,158
+5,998% +$1.18M 0.01% 771
2020
Q3 		$1.45M Buy
+86
New +$23.7K 0.03% 511

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Kestra Advisory Services's VRTX Position: Q1 2026 in Review

Kestra Advisory Services reduced its Vertex Pharmaceuticals (VRTX) stake by 3.3% in Q1 2026, selling an estimated $224K and leaving 13,950 shares worth $6.23M. The position accounts for 0.02% of the portfolio, ranked #680.

Kestra Advisory Services first reported a position in VRTX in Q3 2020 and has held it in 23 quarters since. The position peaked at $9.25M in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Kestra Advisory Services held 13,950 shares of Vertex Pharmaceuticals worth $6.23M as of Q1 2026.
  • Kestra Advisory Services sold 481 Vertex Pharmaceuticals shares in Q1 2026, an estimated $224K.
  • Vertex Pharmaceuticals made up 0.02% of Kestra Advisory Services's portfolio in Q1 2026, its #680 holding.
  • Kestra Advisory Services first reported a position in Vertex Pharmaceuticals in Q3 2020 and has held it in 23 quarters since.
  • Kestra Advisory Services's Vertex Pharmaceuticals position peaked at $9.25M in Q2 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.